Abstract | Background: Methods: A total of 3,049 patients who underwent PCI with bivalirudin as anticoagulant from 27 Chinese medical centers were enrolled. Safety data (AEs/ADRs) were collected from hospital admission to 72 h after bivalirudin administration; then, patients were followed up at the 30th day with the safety data collected as well. Results: A total of 414 (13.58%) patients occurred AEs, among which 31 (1.02%) cases suffered from severe AEs and 8 (0.26%) cases died due to AEs. Importantly, 118 (3.87%) patients occurred bivalirudin related ADRs, among which 7 (0.23%) cases suffered from severe ADRs while no case (0%) died due to ADRs. Of note, 7 (0.23%) patients showed new ADRs, 34 (1.12%) patients experienced bleeding, and 79 (2.59%) patients had thrombocytopenia. Furthermore, age, renal function impairment, CRUSADE high risk stratification independently correlated with total ADRs risk; CRUSADE high risk stratification, emergency operation, full dose bivalirudin independently associated with bleeding risk; age, renal function impairment independently related to thrombocytopenia risk. Conclusion:
Bivalirudin is well-tolerated as an anticoagulant for PCI procedure; meanwhile, older age, renal function impairment, and CRUSADE high risk stratification serve as independent risk factors of bivalirudin related ADRs.
|
Authors | Ping Li, Hongyan Zhang, Caidong Luo, Zheng Ji, Zeqi Zheng, Zhenyong Li, Fan Wu, Jinlong Li, Lang Hong |
Journal | Frontiers in cardiovascular medicine
(Front Cardiovasc Med)
Vol. 8
Pg. 781632
( 2021)
ISSN: 2297-055X [Print] Switzerland |
PMID | 35573935
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Li, Zhang, Luo, Ji, Zheng, Li, Wu, Li and Hong. |